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ISSNObjective: To analyze cases of paradoxical tuberculosis-associated immune recon-
stitution inflammatory syndrome (TB-IRIS) in the CAMbodian Early versus Late Intro-
duction of Antiretrovirals (CAMELIA) randomized trial designed to compare early
(2 weeks) versus late (8 weeks) antiretroviral therapy (ART) initiation after tuberculosis
treatment onset in Cambodia (NCT00226434).
Methods: ART-naive adults with CD4þ cell count of 200 cells/ml or less, newly
diagnosed tuberculosis, and at least one follow-up visit after ART initiation were
included in this analysis. Each case of suspected TB-IRIS was systematically validated
by two physicians not involved in patients’ management. Factors associated with
occurrence of TB-IRIS were identified using the Cox proportional hazard model.
Results: Among 597 patients, 26% experienced TB-IRIS with an incidence rate of 37.9
cases per 100 person-years [95% confidence interval (CI) 32.4–44.4]. Main clinical
manifestations included new or worsening lymphadenopathy (77.4%) and fever
(68.4%). Chest radiograph revealed new or worsening abnormalities in 53.4%. Symp-
toms resolved in 95.5% of patients. Six deaths were directly related to TB-IRIS. Initiating
ART early increased the risk of TB-IRIS by 2.61 (95% CI 1.84–3.70). Extrapulmonary or
disseminated tuberculosis, CD4þ cell count of 100 cells/ml or less, and HIV RNA
concentration more than 6 log10 copies/ml were also significantly associated with
higher risk of TB-IRIS.
Conclusion: Shortening the delay between tuberculosis treatment onset and ART
initiation to 2 weeks was associated with an increased risk of developing TB-IRIS.
However, TB-IRIS was generally easily manageable. Given the marked reportedippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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indicate that fear of TB-IRIS should not be an impediment to early ART in adults with
advanced immunodeficiency in resource-limited, high burden settings.
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Over the past two decades, potent antiretroviral therapy
(ART) has dramatically reduced morbidity, AIDS
progression, and mortality in patients with HIV infection
[1]. However, some individuals experience clinical
deterioration shortly after ART initiation despite
virological efficacy. This phenomenon, known as
immune reconstitution inflammatory syndrome (IRIS)
[2,3], is usually linked with an exaggerated inflammatory
response to either a previously diagnosed and treated
infection (paradoxical IRIS) or to an unrecognized and
untreated infection (unmasking IRIS) [4,5]. IRIS has
been reported to occur in up to 30% of patients after ART
initiation, usually within the first weeks [6–10]. This
syndrome has been associated with: a large number of
pathogens, including Cryptococcus neoformans, cytomega-
lovirus, varicella-zoster virus, hepatitis B and C, JC virus
associated progressive multifocal leukoencephalopathy;
and noninfectious diseases such as Kaposi’s sarcoma,
sarcoidosis and autoimmune disease [11–20]. However,
Mycobacterium tuberculosis, a major cause of mortality
among HIV-infected patients [21], is the most frequent
cause of IRIS [9,22]. In high tuberculosis prevalence
settings, paradoxical tuberculosis-associated IRIS (TB-
IRIS) is a common complication followingART initiation
and is reported to occur in 8–43% of patients [23–26].
Most descriptions of TB-IRIS have been reported from
retrospective analyses or case reports, in which it has been
commonly linked to extrapulmonary and disseminated
tuberculosis, low baseline CD4þ cell count, favorable
response to ART, and a short interval between onset of
tuberculosis treatment and ART initiation [27,28]. The
fearofmanagingTB-IRIS is a common reasonput forward
to delay ART initiation once tuberculosis has been
diagnosed. However, recent publications have shown that
initiating ART early after tuberculosis treatment onset
markedly reduces mortality, particularly in patients with
severe immunosuppression [29–31].
Here, we report the incidence, clinical features, out-
comes, and risk factors of TB-IRIS in HIV-infected
adults enrolled in the CAMELIA trial (ANRS 1295/
CIPRA KH001 DAIDS-ES 10425) with both newly
diagnosed smear-positive tuberculosis and advanced
immunodeficiency.pincott Williams & Wilkins. UnauthoMethods
Study population
CAMELIA was a randomized trial designed to determine
the optimal timing of ART initiation after tuberculosis
treatment onset in Cambodia. From January 2006 to May
2009,weenrolled661HIV-infectedART-naiveadultswith
apositive smear for acid-fastbacilli andCD4þ cell count less
than or equal to 200 cells/ml, as described elsewhere [29].
Following initiation of a standard 6-month tuberculosis
treatment, patientswere randomly assigned to initiate ART
at either 2weeks (early-ARTgroup) or 8weeks (late-ART
group) with a combination of stavudine, lamivudine, and
efavirenz. Randomizationwas stratified according to study
site and CD4þ cell count at enrollment (50 or 51–
200 cells/ml). The trial demonstrated that early initiation of
ART significantly reduced the risk of mortality by 34% as
compared to a later initiation (P<0.006) [29]. Patients
included in the current analysis are those with both
documented tuberculosis (defined here as a positive culture
for M. tuberculosis or positive smear without evidence of
nontuberculous mycobacteria in culture), and at least one
follow-up visit after having initiated ART.
Tuberculosis-associated immune reconstitution
inflammatory syndrome case definition
Characterization of TB-IRIS was a secondary objective of
the CAMELIA trial. TB-IRIS was defined as unexplained
worsening or emergence of symptoms or signs of tuber-
culosis (e.g. fever, cough, shortness of breath, lymph node,
or exacerbation of disease at other extrapulmonary sites)
occurring after ART initiation, in agreement with
previously published definitions [2,3,27,32,33]. Differen-
tial diagnoses such as poor adherence, drug-related side-
effects, and other associated diseases were systematically
considered and excluded. Each case of suspected TB-IRIS
reported by on-site treating physicians was subsequently
validated by at least two experienced physicians, whowere
members of the study team not involved in the day-to-day
management of the patients. Thevalidation processwas not
blinded and reviewers had full access to medical record
documents and outcomes.
Ethics
The trial was approved by the National Ethics Committee
for Health Research of the Cambodian Ministry ofrized reproduction of this article is prohibited.
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Frontie`res, and the Institutional Review Board of
Immune Disease Institute (Boston, Massachusetts,
USA), and conducted according to the principles
expressed in the Declaration of Helsinki. All patients
enrolled in the study gave written, informed consent to
participate. All patient information was entered into a
database using coded identification numbers. No
information that could reveal patient identity was entered
into the database.
Statistical analysis
Baseline characteristics were compared between patients
who did and who did not experience TB-IRIS using x2
test for categorical variables or Student’s t-test for
continuous variables. Delay to TB-IRIS was described
using Kaplan–Meier estimates. Factors associated with
occurrence of TB-IRIS were identified using Cox
proportional hazard model. The proportional hazards
assumption was checked with the use of a test based on
Schoenfeld residuals and was found to be valid for
all factors investigated. All factors associated with
occurrence of TB-IRIS in univariate analysis with a P
value less than 0.20 were entered in the multivariate
model, and a backward stepwise procedure was used to
identify factors that remained significant. A sensitivity
analysis was conducted considering only patients with
culture-confirmed and drug-sensitive M. tuberculosis
strains. We investigated the association between
occurrence of TB-IRIS and mortality using a Cox
proportional hazard model, occurrence of TB-IRIS
being considered as a time-dependent cofactor. Again, a
test based on Schoenfeld residuals was used to check
that the proportional hazard assumption was valid.
Statistical analyses were performed using STATA 11
(Stata Corp. College Station, Texas, USA). TheCopyright © Lippincott Williams & Wilkins. Unaut
Table 1. Distribution of patient characteristics at antiretroviral therapy i
Total (n¼597) Early
Men n (%) 385 (64.5)
Age (years) mean (SD) 36 (7.9)
CD4þ cell count (cells/ml) median (IQR) 26 (12–62)
Viral load (log10 copies/ml) median (IQR) 5.6 (5.2–6.0)
Hemoglobin (g/l) median (IQR) 101 (82–117)
Karnofsky score n (%)
80 329 (55.1)
50–70 252 (42.2)
40 16 (2.7)
BMI (kg/m2) mean (SD) 17.6 (2.5)
ALT >2.50 ULN n (%) 10 (1.7)
Tuberculosis location n (%)
Pulmonary 416 (69.7)
Extrapulmonary 76 (12.7)
Disseminateda 105 (17.6)
Diagnosis of tuberculosis n (%)
Culture confirmed 530 (88.8)
AFB smear þ, culture – 67 (11.2)
AFB, acid-fast bacilli; ALT, alanine aminotransferase; ART, antiretroviral th
limit normal.
aDefined as the presence of both pulmonary and extrapulmonary tuberculCAMELIA trial is registered with ClinicalTrials.gov,
number NCT00226434.Results
Study population
Among the 661 patients enrolled in the CAMELIA trial,
597 individuals (308 in the early-ART group and 289 in
the late-ART group) were considered in this analysis. The
remaining 64 patients were excluded for the following
reasons: 16 patients were infected with nontuberculous
mycobacteria as identified by culture, 37 died, and two
withdrew before ART initiation, whereas nine did not
have a follow-up visit after ART initiation. As shown in
Table 1, male patients represented nearly two-thirds of the
study population. The majority of tuberculosis cases were
pulmonary tuberculosis (69.7%), with 12.7% of extra-
pulmonary tuberculosis and 17.6% disseminated tubercu-
losis. Tuberculosis was confirmed by culture in 88.8% of
cases. At ART initiation, mean age was 36 years [standard
deviation (SD): 7.9],medianCD4þ cell countwas 26 cells/
ml [interquartile range (IQR): 12–62], and median plasma
HIV RNA concentration was 5.6 log10 copies/ml (IQR:
5.2–6.0). Furthermore, patients from the early-ART
group had lower hemoglobin level (P<0.001), Karnofsky
score (P<0.001), and BMI (P<0.001) and higher alanine
aminotransferase level (P¼ 0.021) than patients from the
late-ART group (Table 1).
Incidence and time of occurrence of
tuberculosis-associated immune reconstitution
inflammatory syndrome
Among the 597 patients included in this analysis
who were followed for a median time of 26 monthshorized reproduction of this article is prohibited.
nitiation according to CAMELIA study arm.
-ART group (n¼308) Late-ART group (n¼289) P
200 (64.9) 185 (64.1) 0.81
36 (7.8) 36 (8.1) 0.67
27 (12–62) 26 (13–61) 0.26
5.6 (5.2–6.0) 5.6 (5.2–6.0) 0.71
87 (72–105) 111 (100–123) <0.001
<0.001
100 (32.4) 229 (79.2)
196 (63.6) 56 (19.4)
12 (3.9) 4 (1.4)
17.1 (2.3) 18.2 (2.7) <0.001
9 (2.9) 1 (0.3) 0.021
0.32
213 (69.1) 203 (70.2)
35 (11.4) 41 (14.2)
60 (19.5) 45 (15.6)
0.37
270 (87.7) 260 (90.0)
38 (12.3) 29 (10.0)
erapy; IQR, interquartile range; SD, standard deviation; ULN, upper
osis.
Co
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Weeks 0 4 12 24 36
No. at risk
Early-ART group 308 235 200 187 186
Late-ART group 289 255 241 223 218
No. of TB-IRIS*
Early-ART group 72 100 109 110
Late-ART group 33 43 45 45
* Cumulative
Time from ART initiation (weeks)
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ob
ab
ilit
y 
of
 T
B-
IR
IS
0 4 8 12 16 20 24 28 32 36 40 44 48
Late-ART group
Early-ART group
Logrank test: P < 0.001
0.40
0.30
0.20
0.10
0.00
Fig. 1. Kaplan–Meier estimates of occurrence of tuberculosis-associated immune reconstitution inflammatory syndrome by
study arm. ART, antiretroviral therapy; TB-IRIS, tuberculosis-associated immune reconstitution inflammatory syndrome.(IQR: 15–36), 155 (26%) experienced TB-IRIS. In the
early-ART group, 110 of 308 (36%) patients experienced
TB-IRIS as compared with 45 of 289 (16%) in the late-
ART group (P<0.001). The overall TB-IRIS incidence
rate was 37.9 cases per 100 person-years [95% confidence
interval (CI) 32.4–44.4]. As shown by the Kaplan–Meier
estimate (Fig. 1), occurrence of TB-IRIS was signifi-
cantly higher in the early-ART group than in the
late-ART group with incidences of 58.2 cases per 100
person-years (95% CI 48.3–70.2) and 20.4 cases per 100
person-years (95%CI15.3–27.4), respectively (P<0.001).
The median time between ART initiation and TB-IRIS
was 14 days (IQR: 10–42) and did not differ between
patients enrolled in the early and late-ART groups
(P¼ 0.53). In the majority of patients (143/155),
TB-IRIS occurred during the first 3 months of ART.
Only 11 patients experienced TB-IRIS between 3 and
6 months after ART initiation (nine in the early-
ART group and two in the late-ART group) and one
after 6 months. Interestingly, this later patient was lost to
follow-up, stopped ART for several months, and
developed TB-IRIS within the first month of ART
reintroduction.pyright © Lippincott Williams & Wilkins. UnauthoClinical and radiological features of tuberculosis-
associated immune reconstitution inflammatory
syndrome
The most frequent clinical manifestations of TB-IRIS
were emergence or worsening of lymphadenopathy (120
patients), and fever (106 patients; Table 2). Abdominal
manifestations were also common, including abdominal
pain (44 patients), hepatomegaly (16 patients), and ascites
(15 patients). Neurological manifestations were observed
in eight patients. At the time of TB-IRIS, a chest
radiograph was performed in 103 patients. New or
worsening chest radiograph abnormalities were observed
in 55 patients, the most common being parenchymal
opacities (36 patients), mediastinal lymph node enlarge-
ment (27 patients), and pleural effusion (17 patients).There
were no differences in clinical symptoms of TB-IRIS
between patients in the early and late-ARTgroup,with the
exception of more frequent enlargement of mediastinal
lymph nodes in the late-ART group (P¼ 0.016; Table 2).
Tuberculosis-associated immune reconstitution
inflammatory syndrome treatment and outcome
The median duration of TB-IRIS symptoms was
7.4 weeks (IQR: 4.0–19.8). Of the 155 TB-IRIS cases,rized reproduction of this article is prohibited.
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Table 2. Manifestations, treatment, and outcome of tuberculosis-associated immune reconstitution inflammatory syndrome according to the
timing of antiretroviral therapy initiation.
Total
(n¼155)
Early-ART
group (n¼110)
Late-ART
group (n¼45) P
Symptoms at the time of TB-IRIS, n (%)
Lymph nodes 120 (77.4) 83 (75.5) 37 (82.2) 0.36
Peripheral lymph nodes 94 (60.6) 68 (61.8) 26 (57.8) 0.64
Abdominal lymph nodes 23 (14.8) 18 (16.4) 5 (11.1) 0.40
Mediastinal lymph nodes 27 (17.4) 14 (12.7) 13 (28.9) 0.016
Fever 106 (68.4) 74 (67.3) 32 (71.1) 0.64
Abdominal pain 44 (28.4) 30 (27.3) 14 (31.1) 0.61
Hepatomegaly 16 (10.3) 12 (10.9) 4 (8.9) 0.71
Ascites 15 (9.7) 9 (8.2) 6 (13.3) 0.33
Neurological symptoms 8 (5.2) 6 (5.5) 2 (4.4) 0.80
Chest radiograph performed at the time of TB-IRIS, n (%): 103 (66.5) 74 (67.3) 29 (64.4) 0.10
New or worsening signs 55 (53.4) 36 (48.7) 19 (65.5)
Unchanged 30 (29.1) 26 (35.1) 4 (13.8)
Improved 18 (17.5) 12 (16.2) 6 (20.7)
Treatment received during TB-IRIS, n (%) 0.76
None 41 (26.5) 30 (27.3) 11 (24.4)
NSAID 55 (35.5) 41 (37.3) 14 (31.1)
Steroids 23 (14.8) 15 (13.6) 8 (17.8)
NSAIDþ steroids 36 (23.2) 24 (21.8) 12 (26.7)
Delay from TB-IRIS to NSAID/steroids initiation, days: median (IQR) 5 (1–14) 5 (1–14) 3.5 (0–10) 0.30
Duration of TB-IRIS (weeks): median (IQR) 7.2 (4.0–18.1) 7.2 (4.1–20.0) 7.4 (4.0–14.9) 0.36
Outcome of TB-IRIS, n (%) 0.33
Cured 144 (92.9) 100 (90.9) 44 (97.8)
TB-IRIS-related death 6 (3.9) 6 (5.5) 0 (0.0)
Death not directly attributed to TB-IRIS 5 (3.2) 4 (3.6) 1 (2.2)
ART, antiretroviral therapy; IQR, interquartile range; TB-IRIS, paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.55 patients (35.5%) were treated with NSAIDs for a
median time of 12 days (IQR: 9–24) and 59 patients
(38%) received steroids for a median time of 40 days
(IQR: 24–70; Table 2). Forty-one patients (26.5%) did
not receive any anti-inflammatory treatment. Overall,
more than 92% (144/155) of patients who presented
with TB-IRIS experienced a favorable outcome with
regression of symptoms.
Out of 597 patients, 95 (15.9%) died during the overall
follow-up. There were 23 deaths among the 155 patients
(14.8%) who experienced TB-IRIS and 72 deaths among
the 442 patients (16.3%) who did not experience TB-
IRIS throughout the study. In a Cox proportional hazard
model, there was no association between occurrence of
TB-IRIS and mortality [crude hazard ratio: 0.97 (95%
CI: 0.60–1.57); P¼ 0.91]. Out of the 23 deaths that
occurred in the 155 patients who experienced TB-IRIS,
12 were definitively not related to TB-IRIS and occurred
several weeks or months after resolution of TB-IRIS
(voluntary prolonged interruption of follow-up and ART
for four patients, lactic acidosis for four patients, two
sepsis, one gastrointestinal hemorrhage, and one hemop-
tysis). Six deaths were directly attributed to TB-IRIS, all
in patients from the early-ART group: two had central
neurological disorders (one meningitis and one tubercu-
loma) and four presented with severe abdominal
symptoms related to enlarged inflammatory lymph nodes,
ascites, and abscess. The five remaining deaths could not
be directly attributed to TB-IRIS: stroke was the cause ofCopyright © Lippincott Williams & Wilkins. Unautdeath in a 60-year-old man, while acute severe
hepatotoxicity and intestinal obstruction were noticed
in two patients. Another two patients were found dead at
home a few weeks after initial improvement of TB-IRIS
and hospital discharge. For these five patients, TB-IRIS
might have contributed to the fatal outcome despite not
being the direct cause of death.
CD4R cell count gain and viral load suppression
At ART initiation, CD4þ cell count did not differ
between TB-IRIS and non-TB-IRIS patients [median
(IQR): 27 (12–52) cells/ml and 25 (12–63) cells/ml,
respectively; P¼ 0.06]. After 6 months of tuberculosis
treatment, which corresponded to 24 and 18 weeks of
ART in the early-ART and late-ART groups, respect-
ively, the median CD4þ cell count gain was significantly
higher in patients who experienced TB-IRIS than in
those who did not (P¼ 0.01; Fig. 2). This difference
persisted at one year of follow-up (P¼ 0.02), but not at
later time points measured (up to 48 months). Among
patients with TB-IRIS, median CD4þ cell count gain
was similar at 6 and 12 months of ART in those who
received corticosteroids [120 cells/ml (66–156) and
175 cells/ml (111–222), respectively] and those who
did not [123 cells/ml (83–197) and 176 cells/ml (122–
258), respectively] (P¼ 0.30 and P¼ 0.59, respectively).
The proportion of patients with undetectable HIV RNA
did not differ between those who experienced TB-IRIS
and those who did not at anytime after ART initiation
(Fig. 2).horized reproduction of this article is prohibited.
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Fig. 2. Time course of immunological (upper panel) and
virological (lower panel) outcomes over a 3-year period.
For each time point, the number of patients who experienced
a tuberculosis-associated immune reconstitution inflamma-
tory syndrome (TB-IRIS) is written in bold italic. : P<0.05
(Student’s t-test).Risk factors of tuberculosis-associated immune
reconstitution inflammatory syndrome
In multivariate analysis, factors independently associated
with an increased risk of TB-IRIS were early ART
initiation (P<0.001), extrapulmonary or disseminated
tuberculosis (P<0.001), mediastinal lymphadenopathy
on chest radiograph at enrollment (P¼ 0.004), CD4þ cell
count of 100 cells/ml or less (P¼ 0.048), and HIV RNA
more than 6 log10 copies/ml at ART initiation
(P¼ 0.031; Table 3). A sensitivity analysis considering
only cases with culture positive and drug-sensitive
tuberculosis did not affect these findings (data not shown).Discussion
Our study reports the largest published series of TB-IRIS
in the context of a randomized clinical trial conducted in
severely immunocompromised patients (median CD4þpyright © Lippincott Williams & Wilkins. Unauthocell count: 26 cells/ml). The proportion of paradoxical
TB-IRIS observed during the CAMELIA trial is among
the highest reported. Starting ARTearly after tuberculosis
treatment onset was the strongest risk factor for
developing TB-IRIS. CD4þ cell count below or equal
to 100 cells/ml, viral load higher than 6 log10 copies/ml,
extrapulmonary or disseminated tuberculosis also signifi-
cantly increased this risk.
The CAMELIA trial design allowed us to demonstrate
that the occurrence of TB-IRIS was strongly influenced
by the timing of ART initiation in adults with advanced
immunodeficiency. In multivariate analysis, enrollment in
the early-ART group nearly tripled the risk of developing
TB-IRIS. It might be due, at least in part, to a higher
residual amount of mycobacterial antigen at the time of
early ART initiation. This finding is consistent with data
reported from the Starting Antiretroviral Therapy at
Three Points in Tuberculosis (SAPIT) and AIDS Clinical
Trials Group Study A5221 (STRIDE) trials, which
enrolled less immunocompromised patients who experi-
enced TB-IRIS less frequently [34,35]. A practical
implication of our results is that clinicians and patients
should be prepared to face a temporary worsening after
starting ART early in patients with tuberculosis.
The frequency of TB-IRIS reported in this study is high,
but it is consistent with previous reports [25,36–39].
Reported factors that are often associated with TB-IRIS
include extrapulmonary or disseminated tuberculosis
(presumably because of a high antigen burden), low
CD4þ cell count, and high viral load at ART initiation
[24,40,41]. The majority of our patients (87.3%) had a
CD4þ cell count below 100 cells/ml, which nearly
doubled the risk of developing TB-IRIS when compared
with a CD4þ cell count ranging from 100 to 200 cells/ml.
Similarly, the risk of developing TB-IRIS was doubled in
cases of extrapulmonary or disseminated tuberculosis, or
when HIV RNA was above 106 log10 copies/ml. Thus,
physicians who initiate ART in adults with both CD4þ
cell count below 100 cells/ml and extrapulmonary or
disseminated tuberculosis should be particularly vigilant
regarding potential TB-IRIS. Moreover, detailed and
systematic information about its high frequency and
management should be part of pre-ART counseling in
such patients, similar to what is currently done for
adherence and drug side-effects.
In our study, the time between ART initiation and TB-
IRIS occurrence was similar in the early-ART and late-
ART groups. More than two-thirds of TB-IRIS (105/
155) occurred within the first month of ART and 92%
(143/155) occurred during the first 3 months. These data
are consistent with the definition published by the
International Network for the Study of HIV-associated
IRIS while our study was ongoing, and that set a limit of
3 months between the initiation of ARTand the onset of
TB-IRIS manifestations [27]. However, TB-IRIS casesrized reproduction of this article is prohibited.
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Table 3. Risk factors associated with tuberculosis-associated immune reconstitution inflammatory syndrome (Cox model).
N TB-IRIS N (%) Crude HR (95% CI) P Adjusted HR (95% CI) P
Study arm <0.001 <0.001
Early ART initiation 308 110 (35.7) 2.58 (1.82–3.65) 2.61 (1.84–3.70)
Late ART initiation 289 45 (15.6) 1 1
Sex 0.037
Male 385 111 (28.8) 1
Female 212 44 (20.7) 0.70 (0.49–0.99)
Age (years) 0.64
29 142 41 (28.9) 1
30–39 262 66 (25.2) 0.84 (0.57–1.24)
40 193 48 (24.8) 0.84 (0.56–1.28)
BMI at ART initiation (kg/m2) 0.84
16 160 43 (26.9) 1.16 (0.77–1.75)
16–17 99 27 (27.3) 1.18 (0.74–1.89)
17–18.5 132 36 (27.7) 1.16 (0.75–1.78)
>18.5 206 49 (23.8) 1
Karnofsky score at ART initiation 0.013
80 329 71 (21.6) 1
50–70 252 80 (31.7) 1.62 (1.18–2.23)
40 16 4 (25.0) 1.26 (0.46–3.45)
CD4þ cell count at ART initiation (cells/ml) 0.038 0.048
25 296 74 (25.0) 1.70 (0.92–3.12) 1.58 (0.85–2.91)
26–50 118 39 (33.0) 2.37 (1.24–4.53) 2.35 (1.23–4.51)
51–100 107 30 (28.0) 1.95 (1.00–3.91) 1.80 (0.92–3.55)
>100 76 12 (15.8) 1 1
Viral load at ART initiation (log10 copies/ml) 0.014 0.031
5.00 115 24 (20.9) 1 1
5.01–6.00 330 79 (23.9) 1.18 (0.75–1.87) 1.15 (0.73–1.82)
>6.00 152 52 (34.1) 1.86 (1.15–3.02) 1.74 (1.06–2.84)
Hemoglobin at ART initiation (g/l) <0.001
70 76 31 (40.8) 2.58 (1.67–3.99)
70–85 94 30 (31.9) 1.88 (1.21–2.92)
85–100 116 35 (30.2) 1.69 (1.12–2.57)
>100 311 59 (19.0) 1
ALT at ART initiation 0.20
2.50 ULN 587 154 (26.2) 1
>2.50 ULN 10 1 (10.0) 0.35 (0.05–2.48)
Tuberculosis location 0.001 <0.001
Pulmonary 416 89 (21.4) 1 1
Extrapulmonary 76 28 (36.8) 1.89 (1.23–2.89) 2.06 (1.34–3.17)
Disseminated 105 38 (63.2) 1.94 (1.33–2.84) 1.88 (1.28–2.77)
Tuberculosis drug resistance at enrollment 0.44
No 486 129 (26.5) 1
Yes 101 24 (23.8) 0.89 (0.58–1.38)
Yes, MDR 9 1 (11.1) 0.36 (0.05–2.61)
Chest radiograph at enrollment 0.44
Normal 113 24 (21.2) 1
1 abnormality 211 54 (25.6) 1.22 (0.75–1.97)
2 abnormalities 273 77 (28.2) 1.34 (0.85–2.12)
Mediastinal adenopathy at enrollment 0.003 0.004
No 380 83 (21.8) 1 1
Yes 217 72 (33.2) 1.61 (1.17–2.21) 1.62 (1.17–2.23)
Initial tuberculosis culture 0.68
Negative 67 15 (22.4) 1
Positive for Mycobacterium tuberculosis 530 140 (26.4) 1.35 (0.33–5.46)
ALT, alanine aminotransferase; ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; MDR, multidrug-resistant; TB-IRIS,
paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome; ULN, upper limit normal.have been reported to occur later, even beyond 6 months
post-ART initiation [6,23,37,40,41]. In our study, 11
patients experienced TB-IRIS after 3 months of ARTand
none after 6 months. The only ’very late presentation’
occurred 6 weeks after ART reinitiation in a patient who
had been lost to the trial for 5months.On the basis of these
findings, we suggest that the timing for consensus
definition of TB-IRIS should be extended up to 6months.Copyright © Lippincott Williams & Wilkins. UnautThe most common presentation of TB-IRIS in
CAMELIA included new-onset or enlarging lymph
nodes, fever, and abdominal symptoms (abdominal pain,
ascites, and hepatomegaly). Although these symptoms are
easy to identify, they are nonspecific and are frequently
reported in HIV-infected adults with tuberculosis in
resource-limited settings, which underscores the diffi-
culty of ruling out potential competing diagnoses such ashorized reproduction of this article is prohibited.
Co
2584 AIDS 2013, Vol 27 No 16the occurrence of another opportunistic infection or the
progression of HIV disease. However, we note that
neurological TB-IRIS occurred in only eight patients of
our series, which is lower than what has been previously
reported [42].
In our study, there was no association between
occurrence of TB-IRIS and mortality. TB-IRIS was
not a common direct cause of death: six (3.9%) of patients
who developed TB-IRIS died without another clear
cause of death. Even including the five others in whom
TB-IRIS itself might have contributed to a fatal outcome
despite not being the direct cause of death, case fatality
rate reached 7%, which is relatively low in this very
advanced immunosuppressed population. Notwithstand-
ing this, we do note that the six TB-IRIS events that were
directly assigned as a direct cause of death all occurred in
patients enrolled in the early-ART arm.
We observed a greater CD4þ cell count gain in patients
with TB-IRIS compared with those without TB-IRIS at
6 and 12 months of follow-up, consistent with other
studies [23,37]. However, CD4þ cell gain was similar in
the two groups at the end of follow-up. Of interest, we
did not observe a lower reconstitution of CD4þ cell
count in patients treated with steroids, unlike what has
been reported [43]. Furthermore, we found the same
high percentage of patients with undetectable plasma viral
load in patients with TB-IRIS compared with those
without TB-IRIS during the study duration, up to 90%
from the first year.
A potential limitation of our study is that some forms of
TB-IRIS may not have been recognized by site clinicians,
especially those presentations without fever, lymph node
enlargement, or major clinical symptoms. We note that
these minor forms of TB-IRIS do not require any specific
medical management and spontaneously resolve.
Furthermore, although it was clearly stated in the study
procedures, chest radiograph was not performed in all
suspected cases of TB-IRIS, making it difficult to draw
definite conclusions on the proportion of new or
worsening radiological abnormalities. However, among
the two-thirds of patients who had a chest radiograph at
the time of TB-IRIS, 53% presented new or worsening
radiological abnormalities, whereas at least 29% of
patients with TB-IRIS had no chest radiograph
modification between tuberculosis diagnosis and the
occurrence of TB-IRIS. Although the absence of
worsening or new radiological finding does not rule
out the diagnosis of TB-IRIS, our data suggest that this
simple and noninvasive examination be performed when
an event occurs during the first weeks following ART
initiation, given the reported high frequency of new-
onset or worsening respiratory symptoms and increased
lymphadenopathy in TB-IRIS [44]. Another limitation
of our study was the lack of established criteria to initiate
NSAID or steroids for TB-IRIS. This could explain thepyright © Lippincott Williams & Wilkins. Unauthorelatively high percentage of patients treated with these
drugs as the decision to initiate a specific treatment course
was not standardized across study sites and largely
depended on the site physician’s previous experience,
expert opinion, or data from observational studies
[43,45]. NSAIDs were largely prescribed by clinicians
and steroids were added when the symptoms did not
resolve quickly, or were initiated to treat life-threatening
manifestations. We note that it remains difficult to
provide clear therapeutic recommendations as there are
no clinical data about efficacy of NSAID in TB-IRIS
while steroids have only been shown to reduce morbidity
and hospitalization in a single randomized clinical trial
[46]. However, the management of TB-IRIS in our series
was generally successful and led to more than 90% of
events resolution without any sequelae.
Shortening the delay to initiate ART to 2 weeks after
tuberculosis treatment onset in severely immunocom-
promised HIV-infected adults increased the risk of
developing TB-IRIS, especially when tuberculosis was
extrapulmonary or disseminated. However, TB-IRIS was
clinically manageable and outcome was generally favor-
able. As initiating ARTearly at 2 weeks after tuberculosis
treatment onset provides a marked survival advantage
in severely immunocompromised HIV-infected adults
[29–31] and that there is no association between
occurrence of TB-IRIS and mortality, healthcare
managers should reinforce TB-IRIS training in both
HIV and tuberculosis programs to strengthen the
recognition of this frequent complication by clinicians.
Moreover, pre-ART counseling should include systema-
tic information about TB-IRIS. Finally, our data indicate
that TB-IRIS should not be deterrent to initiate ART
early in resource limited-settings.Acknowledgements
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